Nasdaq

Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets ...

CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis ...
Business Wire

CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets ...

BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China--(BUSINESS WIRE)--Compass Therapeutics, Inc. (OTC:CMPX) and ABL Bio (KOSDAQ: 298380) presented today clinical trial data for CTX-009 (ABL001/ES104) ...
satellitetoday

ABL Space Systems Nearly Doubles Valuation After Closing Additional Series B Funding

Smallsat launcher in development ABL Space Systems has closed a $200 million expansion of its Series B investment round raising the company’s valuation from $1.3 billion to $2.4 billion. The company ...
satellitetoday

ABL Space Systems Lands DoD Launch Contract

ABL Space Systems has won its fourth launch contract with the U.S. Department of Defense. The launcher in development has received a “Responsive Launch II” from the Defense Innovation Unit (DIU). The ...
Business Wire

Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets ...

BOSTON--(BUSINESS WIRE)--Compass Therapeutics, Inc. (OTC:CMPX), a clinical-stage, oncology focused biotechnology company developing proprietary immuno-modulatory and anti-angiogenic antibody ...